Johnson & Johnson heads back to court in Risperdal suit

Company announced $158 million deal with Texas in January over marketing of the drug

The drama surrounding Johnson & Johnson’s (J&J) antipsychotic drug Risperdal is far from over.

Tomorrow, J&J will head back to a Texas courtroom to further discuss the $158 million settlement it had reached with the state in January. The state-specific suit would fully resolve all Risperdal-related claims in Texas, J&J said in January.


Cathleen Flahardy

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.